We believe this technique could potentially transform treatment paradigms for retinal degenerative conditions.” Nie and her ...

At the ARVO 2025 meeting in Salt Lake City, Utah, Nimesh Patel, MD, presented on the LUCIA and LUGANO phase 3 pivotal trials ...

Faricimab demonstrated “rapid improvements” in anatomic features across previously treated and treatment-naïve patients, ...

Currently, there are no medical treatments for early or intermediate age-related macular degeneration (AMD ... risk of exudation, need for therapy, number of intravitreal injections required ...

Vanotech is the sponsor representative and is responsible for the clinical development programme for the therapy in the US.

A single intravitreal injection of UBX1325 (foselutoclax) was shown to be safe in patients with diabetic macular edema. The ...

Patients with neovascular age-related macular degeneration (nAMD) experienced improvements in central macular thickness and ...

D-150 is a potential backbone therapy that is designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and ...

Luxa Biotechnology LLC (Luxa), a clinical-stage biotechnology company developing novel adult retinal pigment epithelial stem ...

4D Molecular Therapeutics (4DMT) has received regenerative medicine advanced therapy (RMAT) designation from the US Food and Drug Administration (FDA) for 4D-150 for diabetic macular oedema.